What we CAN do about chronic allograft nephropathy: Role of immunosuppressive modulations

Kidney International

Volumn 68, Issue 6, 2005, Pages 2429-2443

  Afzali, Behdad ^b   Taylor, Anna L ^b   Goldsmith, David J A ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b NONE

Author keywords

Azathioprine; Chronic allograft nephropathy; Cyclosporine; Immunosuppression; Mycophenolate mofetil; Renal transplant; Sirolimus; Tacrolimus

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; DACLIZUMAB; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; STEROID; TACROLIMUS;

ABSENCE OF SIDE EFFECTS; ARTHRALGIA; BLOOD TOXICITY; CARDIOVASCULAR RISK; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL TRIAL; DIABETES MELLITUS; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG POTENCY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DYSLIPIDEMIA; EDEMA; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; GRAFT SURVIVAL; HERPES ZOSTER; HUMAN; HYPERCHOLESTEROLEMIA; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INFECTIOUS PNEUMONIA; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER TOXICITY; MOUTH ULCER; NEPHROTOXICITY; NONHUMAN; PHYSICIAN; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; REVIEW; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; SURGEON; THEORETICAL STUDY; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT;

EID: 32844454764     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.00720.x     Document Type: Article

References (93)

1. EUROPEAN BEST PRACTICE GUIDELINES FOR RENAL TRANSPLANTATION: Section IV: Long-term management of the transplant recipient. IV.2.6. Chronic graft dysfunction. Late recurrence of other diseases. Nephrol Dial Transplant 17 (Suppl 4):18-19, 2002
2. THE CANADIAN MULTICENTRE TRANSPLANT STUDY GROUP: A randomized trial of cyclosporine in cadaveric renal transplantation. N Engl J Med 309:809-815, 1983
3. PAUL L: Chronic renal transplant loss. Kidney Int 47:1491-1499, 1995
4. CARDARELLI F, SAIDMAN S, THERUVATH T, et al: The problem of late allograft loss in kidney transplantation. Minerva Urol Nefrol 55:1-11, 2003
5. NANKIVELL BJ, BORROWS RJ, FUNG CL, et al: The natural history of chronic allograft nephropathy. N Engl J Med 349:2326-2333, 2003
6. ANDOH TF, BENNETT WM: Chronic cyclosporine nephrotoxicity. Curr Opin Nephrol Hypertens 7:265-270, 1998
7. ISHII Y, SADAWA T, KUBOTA K, et al: Injury and progressive loss of peritubular capillaries in the development of chronic allograft nephropathy. Kidney Int 67:321-332, 2005
8. SCHWARZ A, MENGEL M, GWINNER W, et al: Risk factors for chronic allograft nephropathy after renal transplantation: A protocol biopsy study. Kidney Int 67:341-348, 2005
9. HOLDAAS H, FELLSTROM B, JARDINE AG, et al: Effect of fluvastatin on cardiac outcomes in renal transplant recipients: A multicentre, randomised, placebo-controlled trial. Lancet 361:2024-2031, 2003
10. SIJPKENS YW, JOOSTEN SA, WONG MC, et al: Immunologic risk factors and glomerular C4d deposits in chronic transplant glomerulopathy. Kidney Int 65:2409-2418, 2004
11. BAKKER RC, KOOP K, SIJPKENS YW, et al: Early interstitial accumulation of collagen type I discriminates chronic rejection from chronic cyclosporine nephrotoxicity. J Am Soc Nephrol 14:2142-2149, 2003
12. ALY ZA, YALAMANCHILI P, CORTESE C, et al: C4d peritubular capillary staining in chronic allograft nephropathy and transplant glomerulopathy: An uncommon finding. Transpl Int 18:800-805, 2005
13. CHAPMAN JR, O'CONNELL PJ, NANKIVELL BJ. Chronic renal allograft dysfunction. J Am Soc Nephrol 2005 (Epub ahead of print)
14. JINDAL RM, HARIHARAN S: Chronic rejection in kidney transplants: An in depth review. Nephron 83:13-24, 1999
15. PONTICELLI C: Progrssion of renal damage in chronic rejection. Kidney Int 57 (Suppl):S-62-S-70, 2000
16. GJERTSON DW: Determinants of long term survival of adult kidney transplants: A 1999 UNOS update. Clin Transplant 341-352, 1999
17. GJERTSON DW, CECKA JM: Determinants of long term survival of paediatric kidney grafts reported to the United Network for Organ Sharing Kidney Transplant Registry. Paediatr Transplant 5:5-15, 2001
18. VAZQUEZ MA: Chronic rejection of renal transplants: New clinical insights. Am J Med Sci 320:43-58, 2000
19. CARVALHO MF: Hyperlipidaemia as a risk factor of renal allograft function impairment. Clin Transplant 15:48-52, 2001
20. WISSING KM, ABRAMOWICZ D, BROEDERS N, VEREERSTRAETEN P: Hypercholesterolaemia is associated with increased kidney graft loss caused by chronic rejection in male patients with previous acute rejection. Transplantation 70:464-472, 2000
21. HALLORAN PF, MELK A, BARTH C: Rethinking chronic allograft nephropathy: The concept of accelerated senescence. J Am Soc Nephrol 10:167-181, 1999
22. PILMORE HL, DITTMER ID: Calcineurin inhibitor nephrotoxicity: Reduction in dose results in marked improvement in renal function in patients with coexisting chronic allograft nephropathy. Clin Transplant 16:191-195, 2002
23. GILL JS, TONELLI M, MIX CH, et al: The effect of maintenance immunosuppression medication on the change in kidney allograft function. Kidney Int 65:692-699, 2004
24. MARCEN R, PASCUAL J, TERUEL JL, et al: Outcome of cadaveric renal transplant patients treated for 10 years with cyclosporine: Is chronic allograft nephropathy the major cause of late graft loss? Transplantation 72:57-62, 2001
25. GALLAGHER MP, HALL B, CRAIG J, et al: A randomized controlled trial of cyclosporine withdrawal in renal-transplant recipients: 15 year results. Transplantation 78:1653-1660, 2004
26. PASCUAL M, CURTIS J, DELMONICO FL, et al: A prospective, randomized clinical trial of cyclosporine reduction in stable patients greater than 12 months after renal transplantation. Transplantation 75:1501-1505, 2003
27. ABRAMOWICZ D, MANAS D, LAO M, et al: Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study. Transplantation 74:1725-1734, 2002
28. HERNANDEZ D, ALVAREZ A, TORRES A, et al: Cardiovascular risk profile in nondiabetic renal transplant patients: Cyclosporin versus tacrolimus. Transplant Proc 35:1727-1729, 2003
29. SOLA R, DIAZ JM, GUIRADO L, et al: Tacrolimus in induction immunosuppressive treatment in renal transplantation: Comparison with cyclosporin. Transplant Proc 35:1699-1700, 2003
30. TANABE K: Calcineurin inhibitors in renal transplantation: What is the best option? Drugs 63:1535-1548, 2003
31. MURPHY GJ, WALLER JR, SANDFORD RS, et al: Randomized clinical trial of the effect of microemulsion cyclosporin and tacrolimus on renal allograft fibrosis. Br J Surg 90:680-686, 2003
32. JUREWICZ WA: Tacrolimus versus cyclosporin immunosuppression: Long-term outcome in renal transplantation. Nephrol Dial Transplant 18 (Suppl 1):i7-i11, 2003
33. TOZ H, SEN S, SEZIS M: Comparison of tacrolimus and cyclosporin in renal transplantation by the protocol biopsies. Transplant Proc 36:134-136, 2004
34. BICKNELL GR, WILLIAMS ST, SHAW JA, et al: Differential effects of cyclosporin and tacrolimus on the expression of fibrosis-associated genes in isolated glomeruli from renal transplants. Br J Surg 87:1569-1575, 2000
35. IRISH WS, SHERRILL B, BRENNAN DC, et al: Three-year posttransplant graft survival in renal-transplant patients with graft function at 6 months receiving tacrolimus or cyclosporin microemulsion within a triple-drug regimen. Transplantation 76:1686-90, 2003
36. SOLEZ K, VINCENTI F, FILO RS: Histopathologic findings from 2 year protocol biopsies from a US multicenter kidney transplant trial comparing tacrolimus versus cyclosporin: A Report of the FK506 Kidney Transplant Study Group. Transplantation 66:1736-1740, 1998
37. MORRIS-STIFF GJ, BABOOLAL K, DUNSTAN F, JUREWICZ WA: Conversion from cyclosporin (Neoral) to tacrolimus (Prograf) in renal allograft recipients with chronic graft nephropathy: Results of an observational study. Transplant Int 12:288-292, 1999
38. STOVES J, NEWSTEAD CG, BACZKOWSKI AJ, et al: A randomized controlled trial of immunosuppression conversion for the treatment of chronic allograft nephropathy. Nephrol Dial Transplant 19:2113-2120, 2004
39. LEE WC, LIAN JD, WU MJ, et al: Long-term beneficial effect of tacrolimus conversion on renal transplant recipients. Ren Fail 27:501-506, 2005
40. WAID T, FOR THE CRAF STUDY GROUP: Tacrolimus as secondary intervention vs. cyclosporine continuation in patients at risk for chronic renal allograft failure. Clin Transplant 19:573-580, 2005
41. HOHAGE H, WELLING U, ZEH M, et al: Switching immunosuppression from cyclosporine to tacrolimus improves long-term kidney function: A 6-year study. Transplant Proc 37:1898-1899, 2005.
42. HOLLANDER AA, VAN SAASE JL, KOOTTE AM, et al: Beneficial effects of conversion from cyclosporin to azathioprine after kidney transplantation. Lancet 345:610-614, 1995
43. LIN HY, ROCHER LL, MCQUILLAN MA, et al: Cyclosporin-induced hyperuricemia and gout. N Engl J Med 321:287-292, 1989
44. HAMAR P, LIU S, VIKLICKY O, et al: Cyclosporin A and azathioprine are equipotent in chronic kidney allograft rejection. Transplantation 69:1290-1295, 2000
45. MACPHEE IA, BRADLEY JA, BRIGGS JD, et al: Long-term outcome of a prospective randomized trial of conversion from cyclosporine to azathioprine treatment one year after renal transplantation. Transplantation 66:1186-1192, 1998
46. SWENY P, LUI SF, SCOBLE JE, et al: Conversion of stable renal allografts at one year from cyclosporin A to azathioprine: A randomized controlled study. Transplant Int 3:19-22, 1990
47. PASCUAL J, MARCÉN R, OROfiNO L, et al: Long-term beneficial effects of azathioprine addition to ongoing cyclosporin-prednisone protocol in renal transplantation. Transplant Int 5 (Suppl 1):S107-S109, 1992
48. BAKKER RC, HOLLANDER AA, MALLAT MJ, et al: Conversion from cyclosporin to azathioprine at three months reduces the incidence of chronic allograft nephropathy. Kidney Int 64:1027-1034, 2003
49. ADU D, MICHAEL J, MCMASTER P: Conversion from cyclosporin to azathioprine/prednisolone. Lancet 1:392, 1985
50. MOURAD G, VELA C, RIBSTEIN J, et al: Long-term improvement in renal function after cyclosporine reduction in renal transplant recipients with histologically proven chronic cyclosporine nephropathy. Transplantation 65:661-667, 1998
51. ROSE ML, SMITH J, DUREAU G, et al: Mycophenolate mofetil decreases antibody production after cardiac transplantation. J Heart Lung Transplant 21:282-285, 2002
52. SRINIVAS TR, KAPLAN B, MEIER-KRIESCHE HU: Mycophenolate mofetil in solid-organ transplantation. Expert Opin Pharmacother 4:2325-2345, 2003
53. BLAHETA RA, LECKEL K, WITTIG B, et al: Inhibition of endothelial receptor expression and of T-cell ligand activity by mycophenolate mofetil. Transplant Immunol 6:251-259, 1998
54. COHN RG, MIRKOVIC A, DUNLAP B, et al: Mycophenolic acid increases apoptosis, lysosomes and lipid droplets in human lymphoid and monocytic cell lines. Transplantation 68:411-418, 1999
55. ROSE ML, SMITH J, DUREAU G, et al: Mycophenolate mofetil decreases antibody production after cardiac transplantation. J Heart Lung Transplant 21:282-285, 2002
56. MERVILLE P, BERGE F, DEMINIERE C, et al: Lower incidence of chronic allograft nephropathy at 1 year post-transplantation in patients treated with mycophenolate mofetil. Am J Transplant 4:1769-1775, 2004
57. DUBUS I, VENDRELY B, CHRISTOPHE I, et al: Mycophenolic acid antagonizes the activation of cultured human mesangial cells. Kidney Int 62:857-867, 2002
58. VINCENTI F, RAMOS E, BRATTSTROM C, et al: Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 71:1282-1287, 2001
59. TRAN HT, ACHARYA AM, MCKAY DB, et al: Avoidance of cyclosporine in renal transplantation: Effects of daclizumab, mycophenolate mofetil, and steroids. J Am Soc Nephrol 11:1903-1909, 2000
60. SCHNUELLE P, VAN DER HEIDE JH, TEGZESS A, et al: Open randomized trial comparing early withdrawal of either cyclosporine or mycophenolate mofetil in stable renal transplant recipients initially treated with a triple drug regimen. J Am Soc Nephrol 13:536-543, 2002
61. YANG CW, AHN HJ, KIM WY, et al: Cyclosporine withdrawal and mycophenolate mofetil treatment effects on the progression of chronic cyclosporine nephrotoxicity. Kidney Int 62:20-30, 2002
62. WEIR MR, WARD MT, BLAHUT SA, et al: Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney Int 59:1567-1573, 2001
63. FRANCOIS H, DURRBACH A, AMOR M, et al: The long-term effect of switching from cyclosporin A to mycophenolate mofetil in chronic renal graft dysfunction compared with conventional management. Nephrol Dial Transplant 18:1909-1916, 2003
64. DUCLOUX D, MOTTE G, BILLEREY C: Cyclosporin withdrawal with concomitant conversion from azathioprine to mycophenolate mofetil in renal transplant recipients with chronic allograft nephropathy: A 2-year follow-up. Transplant Int 15:387-392, 2002
65. KHACHATRYAN N, WAUTERS JP, VOGEL P: Effect of mycophenolate mofetil in combination with standard immunosuppression in chronic transplant nephropathy: 1 year experience. Transplant Proc 34:807-808, 2002
66. DUDLEY C, POHANKA E, RIAD H, et al: Mycophenolate mofetil substitution for cyclosporine A in renal transplant recipients with chronic progressive allograft dysfunction: The "Creeping Creatinine" Study. Transplantation 79:466-475, 2005
67. AFZALI B, SHAH S, CHOWDHURY P, et al: Low dose mycophenolate mofetil is effective and safe treatment to permit phased reduction in calcineurin inhibitors in chronic allograft nephropathy. Tranplantation 79:304-309, 2005
68. HENNE T, LATTA K, STREHLAU J: Mycophenolate mofetil-induced reversal of glomerular filtration loss in children with chronic allograft nephropathy. Transplantation 76:1326-1330, 2003
69. GONZALEZ MOLINA M, SERON D, GARCIA DEL MORAL R: Mycophenolate mofetil reduces deterioration of renal function in patients with chronic allograft nephropathy. A follow-up study by the Spanish Cooperative Study Group of Chronic Allograft Nephropathy. Transplantation 77:215-220, 2004
70. KURIATA-KORDEK M, BORATYNSKA M, FALKIEWICZ K, et al: The influence of calcineurin inhibitors on mycophenolic acid pharmacokinetics. Transplant Proc 35:2369-2371, 2003
71. SUWELACK B, GERHARDT U, HOHAGE H: Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy. Am J Transplant 4:655-662, 2004
72. JOLICOEUR EM, QI S, XU D, et al: Combination therapy of mycophenolate mofetil and rapamycin in prevention of chronic renal allograft rejection in the rat. Transplantation 75:54-59, 2003
73. GREGORY CR, HUANG X, PRATT RE, et al: Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. Transplantation 59:655-661, 1995
74. KREIS H, CISTERNE JM, LAND W, et al: Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 69:1252-12560, 2000
75. GROTH CG, BACKMAN L, MORALES JM, et al: Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 67:1036-10342, 1999
76. MORALES JM, WRAMNER K, KREIS H, et al, FOR THE SIROLIMUS EUROPEAN RENAL TRANSPLANT STUDY GROUP: Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant 2:436-442, 2002
77. FLECHNER SM, GOLDFARB D, MODLIN C, et al: Kidney transplantation without calcineurin inhibitor drugs: A prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 74:1070-1076, 2002
78. FLECHNER SM, KURIAN SM, SOLEZ K, et al: De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 4:1776-1785, 2004
79. JOHNSON RW, KREIS H, OBERBAUER R, et al: Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 72:777-786, 2001
80. KREIS H, OBERBAUER R, CAMPISTOL JM, et al: Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 15:809-817, 2004
81. RUIZ JC, CAMPISTOL JM, MOTA A, et al: Early elimination of cyclosporine in kidney transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions. Transplant Proc 35:1669-1670, 2003
82. STALLONE G, DI PAOLO S, SCHENA A, et al: Early withdrawal of cyclosporine A improves 1-year kidney graft structure and function in sirolimus-treated patients. Transplantation 75:998-1003, 2003
83. MAYER AD, DMITREWSKI J, SQUIFFLET JP, et al: Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: A Report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 63:436-443, 1997
84. CIANCIO G, BURKE GW, GAYNOR JJ, et al: A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year. Tranplantation 77:244-251, 2004
85. CIANCIO G, BURKE GW, GAYNOR JJ, et al: A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. Transplantation 77:252-258, 2004
86. PARASKEVAS S, KANDASWAMY R, HUMAR A, et al: Predicting long-term kidney graft survival: can new trials be performed? Transplantation 75:1256-1259, 2003
87. SAUNDERS RN, BICKNELL GR, NICHOLSON ML, et al: The impact of cyclosporine dose reduction with or without the addition of rapamycin on functional, molecular, and histological markers of chronic allograft nephropathy. Transplantation 75:741-742, 2003
88. BUMBEA V, KAMAR N, RISES D, et al: Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant 2005 (Epub ahead of print)
89. HAYDAR AA, DENTON M, WEST A, et al: Sirolimus-induced pneumonitis: Three cases and a review of the literature. Am J Transplant 4:137-139, 2004
90. ROBSON M, COTE I, ABBS I, et al: Thrombotic microangiopathy with sirolimus-based immunosuppression: Potentiation of calcineurin-inhibitor-induced endothelial damage? Am J Transplant 3:324-327, 2003
91. VERONESE FV, MANFRO RC, ROMAN FR, et al: Reproducibility of the Banff classification in subclinical kidney transplant rejection. Clin Transplant 19:518-521, 2005
92. OPELZ G, WUJCIAK T, RITZ E: Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int 53:217-222, 1998
93. OMOTO K, TANABE K, TOKUMOTO T, et al: Use of candesartan cilexetil decreases proteinuria in renal transplant patients with chronic allograft dysfunction. Transplantation 76:1170-1174, 2003